Inclusion Criteria:

          -  Diagnosis of Multiple Myeloma, according to the International Myeloma Foundation 2003
             Diagnostic Criteria

          -  Documented symptomatic myeloma, with organ damage related to myeloma with laboratory
             assessments performed within 21 days of registration

          -  Myeloma that is measurable by either serum or urine evaluation of the monoclonal
             component or by assay of serum free light chains.

          -  ECOG performance status </= 2

          -  Negative HIV blood test

          -  Voluntary written informed consent

        Exclusion Criteria:

          -  Pregnant or lactating female

          -  Prior systemic therapy for MM (localized radiotherapy allowed if at least 7 days
             before study entry, corticosteroids allowed if dose </= equivalent of 160 mg
             dexamethasone over 2 weeks)

          -  Primary amyloidosis (AL) or myeloma complicated by amylosis

          -  Receiving any other investigational agents

          -  Known brain metastases

          -  Poor tolerability or allergy to any of the study drugs or compounds of similar
             composition

          -  Platelet count <50,000/mm3, within 21 days of registration

          -  ANC <1,000 cells/mm3, within 21 days of registration

          -  Hemoglobin <8 g/dL, within 21 days of registration

          -  Hepatic impairment (>/= 1.5 x institutional ULN or AST (SGOT), ALT (SGPT), or alkaline
             phosphatase >2 x ULN). Patients with benign hyperbilirubinemia are eligible.

          -  Renal insufficiency (serum creatinine >2.0 mg/dl or creatinine clearance <50 ml/min,
             within 21 days of registration)

          -  Respiratory compromise (DLCO < 50%)

          -  Clinical signs of heart or coronary failure or LVEF < 40%. Myocardial infarction
             within 6 months prior to enrollment, NYHA Class III or IV heart failure, uncontrolled
             angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence
             of acute ischemia or active conductive system abnormalities

          -  Intercurrent illness including, but not limited to ongoing or active severe infection,
             known infection with hepatitis B or C virus, poorly controlled diabetes, severe
             uncontrolled psychiatric disorder or psychiatric illness/social situations that would
             limit compliance with study requirements

          -  Previous history of another malignant condition except for basal cell carcinoma and
             stage I cervical cancer. If malignancy was experienced more than 2 years ago and
             confirmed as cured, these participants may be considered for the study on case by case
             basis with PI discussion.

          -  Inability to comply with an anti-thrombotic treatment regimen

          -  Peripheral neuropathy >/= Grade 2